Benralizumab is more effective than prednisolone in treating eosinophilic exacerbations in patients with asthma and COPD.

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

A psychoeducational intervention for extrapulmonary manifestations of severe asthma was found feasible and rated as ...

Medicare has chosen 15 prescription medications for price negotiations this year, building off a first round of negotiations ...

Company has also raised $12 million in funding led by Lucius Partners NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- AerWave Medical, a leader in ultrasound-based interventional pulmonary solutions, ...

Winter is closely linked to an increase in respiratory infections, as it is considered a season of heightened allergies and ...

About Fexlamose Fexlamose is being developed as a chronic treatment for COPD and asthma in conjunction with standard therapies, to improve lung function, lessen symptoms and improve quality of life.

The Pneumatic Nebulizer market is expected to grow from an estimated USD 815.5 million in 2024 to USD 1.47 billion in 2033, at a CAGR of 6.80% VANCOUVER, BRITISH COLUMBIA, CANADA, January 16, 2025 ...

Its a giant step for pediatric asthma care as this nasopharyngeal swab test marks an improvement Paired with the right ...

In asthma, lower end-tidal carbon dioxide may predict acute exacerbation outcomes, although other measures may be better severity indicators.

MRI of inhaled perfluoropropane can assess regional lung ventilation and monitor improvements in response to medication ...

The study, involving five patients, demonstrated the procedural efficiency and feasibility of AerWave's technology.